Given B7-H3 is often overexpressed in mCRPC, particularly those with HRD, we evaluated the antitumour activity of DS-7300a, a TOP1-inhibitor payload anti-B7-H3 ADC in tumours with varying levels of B7-H3 expression and genomic backgrounds including HRD. This evidence concerns the gene CD276 and neoplasm.